Entera Bio shares rise 13.64% premarket after director Steven D. Rubin's SEC filing reveals 5,000-share purchase.

Entera Bio surged 13.64% in premarket trading following the disclosure of a Securities and Exchange Commission filing revealing that Director Steven D. Rubin purchased 5,000 shares at $1.49 each, increasing his total holdings to 15,000 shares. The transaction, valued at $7,450, was signed by attorney-in-fact Dana Yaacov-Garbeli and likely signaled insider confidence.